- Home
- ANVS vs IKNA Comparison
ANVS vs IKNA Comparison
Compare ANVS & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- IKNA
- Stock Information
- Founded
- ANVS 2008
- IKNA 2016
- Country
- ANVS United States
- IKNA United States
- Employees
- ANVS N/A
- IKNA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- IKNA Health Care
- Exchange
- ANVS Nasdaq
- IKNA Nasdaq
- Market Cap
- ANVS 44.6M
- IKNA 63.7M
- IPO Year
- ANVS 2020
- IKNA 2021
- Fundamental
- Price
- ANVS $2.75
- IKNA $1.36
- Analyst Decision
- ANVS Strong Buy
- IKNA Strong Buy
- Analyst Count
- ANVS 4
- IKNA 1
- Target Price
- ANVS $18.00
- IKNA $4.00
- AVG Volume (30 Days)
- ANVS 437.3K
- IKNA 60.0K
- Earning Date
- ANVS 08-14-2025
- IKNA 08-07-2025
- Dividend Yield
- ANVS N/A
- IKNA N/A
- EPS Growth
- ANVS N/A
- IKNA N/A
- EPS
- ANVS N/A
- IKNA N/A
- Revenue
- ANVS N/A
- IKNA N/A
- Revenue This Year
- ANVS N/A
- IKNA N/A
- Revenue Next Year
- ANVS N/A
- IKNA N/A
- P/E Ratio
- ANVS N/A
- IKNA N/A
- Revenue Growth
- ANVS N/A
- IKNA N/A
- 52 Week Low
- ANVS $1.11
- IKNA $0.97
- 52 Week High
- ANVS $14.80
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- ANVS 57.81
- IKNA 53.81
- Support Level
- ANVS $2.24
- IKNA $1.31
- Resistance Level
- ANVS $2.97
- IKNA $1.42
- Average True Range (ATR)
- ANVS 0.26
- IKNA 0.05
- MACD
- ANVS 0.02
- IKNA -0.00
- Stochastic Oscillator
- ANVS 65.58
- IKNA 45.45
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.